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Context: Abnormal growth and short stature are observed in patients with mitochondrial disease,
but it is unclear whether there is a relationship between final adult height and disease severity.
Objective: To determine whether patients with genetically confirmed mitochondrial disease are
shorter than their peers and whether stature is related to disease severity.
Design: Analysis of final adult height in relation to disease severity as determined by the Newcastle
Mitochondrial Disease Adult Scale (NMDAS).
Setting: UK Mitochondrial Disease Patient Cohort (Mito Cohort).
Patients: 575 patients were identified with recorded height, weight, and molecular genetic di-
agnosis of mitochondrial disease within the Mito Cohort.
Main Outcome Measures: Adult height, body mass index (BMI), and their association with genetic
subgroup and disease severity.
Results: Adults with mitochondrial disease were short, with a mean height of 20.49 SD (95%
CI, 20.58 to 20.39; n = 575) compared with UK reference data. Patients were overweight, with a
BMI SD of 0.52 (95% CI, 0.37 to 0.67; n = 472). The most common genetic subgroup (m.3243A.G
mutation) had a height SD of 20.70 (95% CI, 20.85 to 20.54; n = 234) and a BMI SD of 0.12 (95%
CI,20.10 to 0.34; n = 212). NMDAS scores were negatively correlatedwith height SD (r =20.25; 95%
CI, 20.33 to 20.17; P , 0.001, n = 533). Rate of disease progression also correlated negatively with
adult height (P , 0.001).
Conclusion: Final height in mitochondrial disease reflects disease severity and rate of disease
progression. Mitochondrial dysfunction and associated subclinical comorbidities affect growth
plate physiology. (J Clin Endocrinol Metab 104: 2057–2066, 2019)
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Mitochondrial disease has an estimated prevalence of1 in 4300 adults (1). Disease can present with
multisystem involvement, but neurologic features often
predominate (2). Poor growth and short stature are well
recognized in affected patients, yet the precise mecha-
nisms resulting in growth failure are poorly understood.
Mitochondria are essential organelles found in all nu-
cleated cells. Mitochondria have multiple roles in cellular
metabolism, including a fundamental role in ATP synthesis
through the process of oxidative phosphorylation. Mito-
chondria contain their own DNA [mitochondrial DNA
(mtDNA)] encoding 37 genes. Thousands of copies of
mtDNA may exist in an individual cell. One of several
unique features of the mitochondrial genome is hetero-
plasmy, the coexistence of both mutated and wild type
mtDNA within the same cell or tissue. Mutated mtDNA is
often well tolerated at low levels of heteroplasmy, but
once a specific threshold is exceeded, cellular and organ
functions are disrupted (2). There are.1100mitochondrial
proteins encoded by nuclear genes, which are involved in
the replication, translation, andmaintenance of mtDNA, as
well as other aspects of mitochondrial function (3). Mi-
tochondrial disease can therefore arise as a consequence of a
mutation in either mtDNA or the nuclear genome. In either
case, the adverse impact on ATP generation is detrimental
to organs with high energy demands such as the brain,
heart, liver, and skeletal muscle.
The Newcastle Mitochondrial Disease Adult Scale
(NMDAS) is a validated clinical scale used to assess mul-
tisystem involvement and disease progression. NMDAS
explores all aspects of mitochondrial disease, focusing on
current function and current clinical assessment, including
system-specific involvement and quality of life (4). NMDAS
is routinely performed on patients attending outpatient
review by their neurologists in Newcastle Upon Tyne every
12 to 24 months. A lowNMDAS score suggests the patient
is asymptomatic or has low disease burden, whereas a high
score reflects severe multisystem involvement.
The increase in height observed during childhood and
adolescence is under the control of numerous factors,
with a key physiological endpoint being growth and
multiplication of growth plate chondrocytes (5). Mito-
chondrial dysfunction therefore has potential to un-
dermine the growth process. Wolny et al. (6) reported that
children with mitochondrial disease are about 21.97 SD
shorter than their unaffected peers, with an associated
BMI reduction of 21.07 SD (7). The m.3243A.G
mutation in MT-TL1 is the most common pathogenic
mutation of mitochondrial disease and is commonly
associated with short stature; 73% of a Chinese cohort
of pediatric patients with this mutation were identified
as being short (8). A similar observation was reported
in a Japanese cohort, although a Dutch study found that
short stature was observed only in female patients with
mitochondrial disease (8–10). Patients with mitochon-
drial disease may not become symptomatic until
adulthood, but they may still be shorter than expected,
which suggests a subclinical effect the on growth plate
metabolism.
We hypothesized that adults with mitochondrial
disease would be shorter than their peers and that their
stature would be related to disease severity and genetic
subgroup.
Subjects and Methods
We undertook a retrospective analysis of height, weight, and
molecular genetic data from the UK Mitochondrial Disease
Patient Cohort (Mito Cohort), collected from inception in
March 2009 to February 2017. All patients provided informed
consent when joining the Mito Cohort, a database of patients
with genetically determined or biochemical evidence of mito-
chondrial disease. Data analysis was approved by the Mito-
chondrial Disease Cohort Oversight Committee. Height and
body mass index (BMI) were converted to SDs based on UK
reference data (British 1990 growth reference centiles) (11). The
overall disease severity of individual patients was evaluated
with the NMDAS, with the most recent score used in the
analysis (4, 12).
We determined the relationship between final height and
NMDAS scores in all adult patients where data were available.
Additional analysis was conducted in specific groups of pa-
tients. They included patients with m.3243A.G, single large-
scale mtDNA deletion, and nuclear gene defects. This analysis
allowed us to determine whether there was any difference in the
association of height, BMI, and NMDAS between genotypes.
The m.3243A.Gmutation is the single most common cause of
mitochondrial disease (1). In patients with m.3243A.G mu-
tation, age-adjusted blood heteroplasmy levels were also ana-
lyzed (13). In the single, large-scale mtDNA deletion group, we
performed additional analysis by looking at Kearns-Sayre
syndrome (KSS), chronic progressive external ophthalmoplegia
and ptosis (CPEO), and CPEO plus (CPEO+) because those with
KSS are known to have early-onset disease, whereas those with
CPEO and CPEO+ present later in life (2).
Normality testing was performed before statistical analysis,
with nonnormally distributed data subject to square root
transformation before parametric testing. The square root of
NMDAS score was therefore included in all described analyses
(13). The independent samples t test was used to compare
means between two groups. ANOVA was used to compare
means between multiple groups; subsequent comparisons be-
tween groups were evaluated with Bonferroni-corrected t tests.
The association of two continuous variables was tested via
Pearson correlation. All means are displayed with 95% CIs
unless otherwise stated. The statistical significance threshold
was set at P , 0.05 for all tests.
We determined the relationship between final adult height
and BMI between disease manifestations as defined by ques-
tions in the NMDAS score with Pearson correlation. To
quantify the association between height SD, BMI SD, age, and
progression of disease burden, we used the Linear and
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Nonlinear Mixed Effects Models package to perform a linear
mixed effects analysis of the relationship between heteroplasmy
level, age, and NMDAS scaled score (14). As fixed effects we
entered age and height SD or BMI SD into the model. As
random effects we had by-subject random slopes for the effect
of age. Two-sided P values were obtained from the t distribution
reported in Linear and Nonlinear Mixed Effects Models.
In our cohort we are not aware of any patients with mi-
tochondrial disease who have been treated with GH. Short
stature due to mitochondrial disease is not an indication for GH
treatment in the United Kingdom (15).
Results
A total of 891 participants were enrolled in the Mito
Cohort in Newcastle, of whom 797 patients were
aged$18 years by January 2017. A total of 222 patients
were excluded because of a lack of recorded height (n =
143), no established genetic cause (n = 78), or a height
data entry error (n = 1). A total of 575 adults aged 18 to
85 years at the time of their height measurement, were
identified with genetic evidence of mitochondrial disease
and growth data available (Table 1). Of these, 38.3%
were male (n = 220) and 61.3% female (n = 355).
The height recorded at$18 years of age was assumed
to be the patient’s final height. In 38 patients, the date of
height measurement was not documented; for these
patients final height was assumed to be their consent date
for entry in the cohort, provided they were.18 years old.
Subsequent analysis was performed on all patients and
specific heterogeneous groups: m.3242A.G (n = 234),
nuclear gene defects (n = 146), and single large-scale
mtDNA deletions (n = 90). We omitted other mtDNA
mutations (n = 107) because the sample size for each
genotype was insufficient.
Age
The mean age at height measurement of patients
recruited to the cohort was 46.1 years (95% CI, 44.8 to
47.5; n = 538). The date height was taken was not
available for 38 patients (Table 1). The mean age at
height measurement in the m.3243A.G group was 42.4
years (95% CI, 40.6 to 44.3; n = 226), in the single large-
scale deletion group it was 47.3 years (95% CI, 44.0 to
50.6; n = 84), and in the nuclear gene defect group it was
53.5 years (95% CI, 50.5 to 56.5; n = 129).
There was a significant difference betweenmean age at
height measurement between the genetic subgroups, as
determined by one-way ANOVA [F(2, 436) = 21.38, P,
0.001]. A multiple comparison, using Bonferroni cor-
rected t tests, revealed that the mean age at height
measurement was significantly lower in the m.3243A.G
group than in the nuclear gene defect group (mean
difference = 211.09; 95% CI, 215.17 to 27.00; P ,
0.001) and the single large scale deletion group (mean
difference =24.85; 95%CI,29.58 to20.12; P = 0.042).
There was also a significant difference in the age at height
Table 1. Cohort Demographics
Genetic
ID
Genetic
Diagnosis
Number
of
Patients Male Female
Mean Age
at Height
Measurement
Age
Range
Mean
Height
SD
95% CI of
the Mean for
Height SD
Number
of Patients
With
BMI
Mean
BMI SD
95% CI of
the Mean
for BMI SD
All cohort 575 220 355 46 18–85 20.49 20.58 to 20.39 472 0.52 0.37 to 0.67
Primary mtDNA mutations
m.14709T.C 11 1 10 48 26–64 0.30 20.57 to 1.17 7 20.24 23.00 to 2.53
m.3243A.G 234 95 139 42 18–79 20.70 20.85 to 20.55 212 0.12 20.10 to 0.34
m.8344A.G 40 13 27 45 20–69 20.41 20.72 to 20.11 28 0.66 20.01 to 1.34
Single large-scale
mtDNA deletion
90 34 56 47 18–85 20.27 20.52 to 20.03 78 0.68 0.33 to 1.03
Othera 54 20 34 42 20–77 20.33 20.59 to 20.06 40 0.72 0.23 to 1.20
Nuclear DNA mutations
OPA1 17 5 12 46 18–72 20.28 20.91 to 0.35 13 2.11 1.56 to 2.67
POLG 27 11 16 49 19–80 20.09 20.50 to 0.31 19 1.00 20.03 to 1.96
RRM2B 17 5 12 59 31–76 20.30 20.88 to 0.29 14 0.97 0.34 to 1.60
TWINK 40 15 25 58 18–82 20.42 20.73 to 20.11 32 1.32 0.79 to 1.85
Other multiple
deletion
27 12 15 63 45–77 20.69 21.22 to 20.16 15 1.27 0.64 to 1.91
Otherb 18 9 9 39 18–81 20.66 21.24 to 20.09 14 0.00 21.60 to 1.61
aOther primary mtDNA mutations include m.11778G.A, m.12147G.A, m.12148T.C, m.12258C.A, m.12271T.C, m.12283A.G, m.12315G.A,
m.12320A.G, m.13051A.G, m.13094T.C, m.13513G.A, m.14674T.C, m.15699G.C, m.16002T.C, m.16023G.A, m.1624C.T, m.3243A.T,
m.3365T.C, m.3460G.A, m.4175G.A, m.4267A.G, m.4298G.A, m.4300A.G, m.5543T.C, m.5650A.G, m.5690A.G, m.618T.G,
m.7497G.A, m.7587T.C, m.7989T.C, m.8839G.C, m.8851T.C, m.8993T.C, m.8993T.G, m.9176T.C, and m.9185T.C.
bOther nuclear DNA mutations include the following: AFG3L2 encodes AFG3-like protein 2, ETFDH encodes electron transfer flavoprotein de-
hydrogenase, GFER encodes growth factor augmenter of liver regeneration, MTFMT encodes mitochondrial methionyl-tRNA formyltransferase, OPA1
encodes dynamin-like 120-kDa protein, PDH encodes pyruvate dehydrogenase complex, POLG encodes the a-subunit of mitochondrial polymerase-g,
RRM2B encodes ribonucleotide reductase regulatory TP53 inducible subunit M2B, SDHA encodes succinate dehydrogenase complex subunit A, SPG7
encodes paraplegin, TRIT1 encodes tRNA isopentenyltransferase, TWNK (previously also known as PEO1) encodes twinkle helicase, TYMP encodes
thymidine phosphorylase, and YARS2 encodes tryosyl-tRNA synthetase.
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measurement between the single large-scale deletion
group and nuclear groups (mean difference = 26.23;
95% CI, 211.42 to 21.05; P = 0.012).
Height
There was no significant difference in the mean height
SD score (SDS) between men (mean = 20.42; SD 1.13;
95% CI, 20.57 to 20.27; n = 220) and women
[mean = 20.52; SD 1.18; 95% CI, 20.65 to 20.40; n =
335; t(573) = 1.02; P = 0.307; 95% CI, 20.94 to 0.29].
The 575 adults with mitochondrial disease were shorter
than the general population, with a mean SD for height
of 20.49 (95% CI, 20.58 to 20.39) (Table 1, Fig. 1).
Furthermore, 34.6% (n = 199) of adults had a height.1
SD below the mean, and 10% (n = 57) of adults had a
height .2 SD below the mean.
The mean height SD of the m.3243A.G subgroup
was 20.70 (95% CI, 20.85 to 20.54; n = 234), in the
single large-scale deletion group it was 20.27 (95%
CI, 20.52 to 20.03; n = 90), and in the nuclear group it
was 20.41 (95% CI, 20.59 to 20.22; n = 146). There
was a significant difference in mean final height SDs
between genetic subgroups as determined by one-way
ANOVA [F(2, 467) = 5.37, P = 0.005]. Multiple com-
parison (Bonferroni corrected) revealed that the mean
final height SDwas significantly lower in them.3243A.G
group than in the single large-scale deletion group (mean
difference =20.43; 95%CI,20.77 to20.08; P = 0.011).
There was no difference between the m.3243A.G and
nuclear groups (mean difference =20.29; 95%CI,20.59
to 0.01; P = 0.057). There was no significant difference
between the single large-scale deletion group and the
nuclear deletion group (mean difference = 0.13; 95%
CI,20.51 to 0.24; P = 1.000). In the m.3243A.G group,
42% (n = 102) had a height of ,1 SD below the UK
reference data, and 15% (n = 36) had a height ,2 SD
below the UK reference data.
There is limited data on when patients with mito-
chondrial disease attain their final height and whether
this timing is delayed. In our cohort, final adult height
was not significantly lower in the patients whose
heights were recorded between 18 and 25 years of age
(mean = 20.73; SD 1.32; 95% CI, 21.09 to 20.38; n =
55) compared with those where height was recorded
at .25 years of age [mean = 20.46; SD 1.10; 95%
CI, 20.56 to 20.36; n = 482; t(535) = 21.69; P = 0.092;
95% CI, 20.59 to20.64]. This equates to a mean height
of 159.2 cm for women and 172.5 cm for men,25 years
andmean height of 160.9 cm for women and 174.1 cm for
men .25 years.
In an analysis of the single large-scale mtDNA de-
letion, patients with KSS had a mean height SD of21.41
(95% CI, 22.31 to 20.51; n = 11), patients with CPEO
had a mean height SD of 0.33 (95% CI,20.15 to20.81;
n = 20), and those with CPEO+ had a mean height SD
of 20.28 (95% CI, 20.59 to 0.02; n = 50).
BMI
In total, 82.1% (n = 472) of patients had a recorded
weight, which was used to calculate BMI SD. The mean
weight in men (75.4 kg; 95% CI, 72.6 to 78.3; n = 182)
was higher than in women (63.6 kg; 95% CI, 61.7 to
65.5; n = 290). There was no significant difference in BMI
SD between men (mean = 0.48, SD 1.84, n = 182) and
women [mean = 0.54, SD 1.62, n = 290; t(470) = 20.37;
P = 0.713; 95% CI, 20.353 to 0.288] (Table 1).
A mean BMI SD of 0.52 (95% CI, 0.37 to 0.67; n =
472) was above average when compared with UK
standards [Fig. 1(b)]. The mean BMI SD for the
m.3243A.G group was 0.12 (95% CI, 20.10 to 0.34;
Figure 1. Individual boxplots of height SD and BMI SD for genotypes. Boxplots showing the median, first quartile, third quartile, and range for
(a) height SD and (b) BMI SD for the cohort and each genotype.
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n = 212), for the single large-scale deletion group it was
0.68 (95% CI, 0.33 to 1.03; n = 78), and for the nuclear
group it was 1.13 (95% CI, 0.80 to 1.46; n = 107). There
was an observed difference in mean BMI SD [F(2, 394) =
14.04, P , 0.001] between the genetic subgroups.
Multiple comparisons revealed that the m.3243A.G
subgroup had a lower mean BMI SD than the single
large-scale deletion group (mean difference = 20.55;
95% CI, 21.08 to 20.04; P = 0.032) and the nuclear
group (mean difference = 21.01; 95% CI, 21.48
to 20.54; P , 0.001).
Further analysis of single, large-scale mtDNA deletion
data showed that patients with KSS had a mean BMI SD
of 20.55 (95% CI, 22.02 to 0.92; n = 9), patients with
CPEO had a mean BMI SD of 1.02 (95% CI, 0.31 to
1.74; n = 18), and those with CPEO+ a mean BMI SD of
0.78 (95% CI, 0.35 to 0.78; n = 46).
NMDAS
A total of 533 adults had a documented height and
NMDAS score. NMDAS scores were negatively corre-
lated with height SDS (Pearson correlation coefficient
r =20.25; 95%CI,20.33 to20.17; P, 0.001; n = 533)
(Fig. 2). A weaker correlation was observed between the
NMDAS score and BMI SD (r = 20.10; 95% CI, 20.19
to 20.01; P = 0.033; n = 439).
In the m.3243A.G group the NMDAS score was
negatively correlated with the height SD (r = 20.39; 95%
CI, 20.50 to 20.27; P , 0.001; n = 222). The NMDAS
score was also negatively correlated with BMI SDS in this
subgroup (r =20.32; 95%CI,20.44 to20.20; P, 0.001;
n = 201). In the single, large-scale mtDNA deletion group
the NMDAS score was negatively correlated with height
SDS (r = 20.30; 95% CI, 20.47 to 20.12; P = 0.006; n =
82); however, there was no association between BMI and
NMDAS score (r = 20.18; 95% CI, 20.37 to 0.043; P =
0.130; n = 72). In the nuclear deletion group the NMDAS
score was negatively correlated with height SDS
(r =20.193; 95%CI,20.34 to20.03; P = 0.027; n = 131).
There was no correlation between BMI and NMDAS score
(r = 0.12; 95% CI, 20.06 to 0.30; P = 0.262; n = 96).
Mean NMDAS score of those ,25 years of age when
height was recorded was 23 (95% CI, 16.3 to 29.9; n =
46), and the NMDAS score of those .25 years of age
when height was recorded was 26 (95%CI, 24.6 to 28.1;
n = 453). NMDAS score was negatively correlated with
the height SD of patients ,25 years of age when height
was recorded (r = 20.43; 95% CI, 20.63 to 20.18; P =
0.003; n = 46) and .25 years when height was recorded
(r = 20.22; 95% CI, 20.31 to 20.14; P , 0.001;
n = 453).
Heteroplasmy
Age-corrected blood mutant heteroplasmy was ex-
plored in our largest subgroup, m.3243A.G (13). Data
were available for 92.3% (n = 216) of patients with
m.3243A.G. NMDAS score was positively correlated
with age-corrected blood heteroplasmy level (r = 0.36;
95% CI, 0.28 to 0.47, P , 0.001). The age-corrected
blood heteroplasmy level was negatively correlated with
height (r =20.31; 95% CI,20.42 to20.18; P, 0.001)
and BMI (r = 20.39; 95% CI, 20.50 to 20.26, P ,
0.001) SDs.
Patient-reported disease onset
Further information with regard to patient-reported
symptom onset was explored in the two largest sub-
groups with the m.3243A.G mutation and single large-
scale mtDNA deletions. In the m.3243A.G group, onset
data were available for 86.8% (n = 166) of patients, of
whom 18.2% (n = 37) were asymptomatic carriers. The
mean age of onset of patients in the m.3243A.G group
Figure 2. Individual boxplots of height SD against NMDAS score. Boxplots showing the median, first quartile, third quartile, and range for
height SD (a) all cohort and (b) m.3243A.G against NMDAS score. All cohort n = 533, and m.3243A.G n = 222.
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was 28.5 years (95% CI, 26.5 to 30.6; n = 166). Age of
onset was available for 96.7% (n = 87) of patients with
single large-scale deletions, and the mean age of onset
was 23.7 years (95% CI, 21.07 to 26.47; n = 87).
In the m.3243A.G mutation group a positive cor-
relation was identified between age of onset and height
SD (r = 0.28; 95% CI, 0.13 to 0.41; P# 0.001; n = 166),
indicating that later onset was associated with taller final
adult height. A positive correlation was also identified
between age of onset and BMI SD (r = 0.27; 95%CI, 0.12
to 0.41; P # 0.001; n = 155). No correlation was
identified between NMDAS score and age of onset
(r =20.10; 95% CI,20.25 to 0.06; P = 0.220; n = 159).
In the single, large-scale mtDNA deletion group no
relationship was observed between age of onset and final
adult height SD (r = 0.010; 95% CI, 20.20 to 0.22; P =
0.912; n = 87), BMI SD (r = 0.05; 95% CI, 20.18. to
0.27; P = 0.678; n = 77), or NMDAS score (r = 20.17;
95% CI, 20.37 to 0.07; P = 0.136; n = 80). In patients
with KSS, the mean age of onset was earlier, at 11.1
(66.2) years of age, compared with other genetic groups.
Disease manifestations and progression
There were 400 patients with multiple NMDAS
measurements: 174 in the m.3243A.G subgroup, 90 in
the nuclear group, 71 with single deletions, and 65 in the
other subgroup. The median number of NMDAS as-
sessments was 4 (interquartile range = 4.00; range = 2 to
22), with a median interval between NMDAS assess-
ments of 5.20 years (interquartile range = 5.85; range = 0,
13.3). Longitudinal linear mixed modeling, used to ex-
amine the role of height and BMI in the rate of NMDAS
development, revealed a significant negative association
between height SD and increased disease progression in
the whole cohort (P # 0.001). This association was
drivenmainly by them.3243A.G subgroup (P# 0.001).
The nuclear gene defects and single large-scale mtDNA
deletion groups showed no significant association (P =
0.197 and P = 0.144, respectively).
A similar picture was seen when BMI SD was con-
sidered. The significant association with increased dis-
ease progression in the whole cohort (P # 0.001) was
drivenmainly by them.3243A.G subgroup (P# 0.001),
although the single large-scale mtDNA deletion sub-
group also showed a significant effect (P = 0.021). The
nuclear subgroups showed no association (P = 0.188).
Height SD was negatively correlated with several
specific NMDAS fields, namely cerebellar ataxia, cogni-
tion, pyramidal involvement, hearing impairment, gas-
trointestinal disturbance, diabetes, and cardiovascular
involvement (range of r = 20.17 to 20.28, all P ,
0.001; Table 2). Interestingly, although hearing im-
pairment and gastrointestinal disturbance are also
associated with BMI SD (r for both =20.17, P, 0.001),
BMI SD is independently associated with four other
phenotypes not associated with height SD (dysphonia or
dysarthria, seizures, encephalopathy, and strokelike
episodes; range of r is 20.16 to 0.21, P , 0.001).
Discussion
Our findings in a large cohort of well-characterized
patients supports earlier work indicating that patients
with mitochondrial disease are shorter than their peers.
In addition, we describe associations between disease
severity as measured by the NMDAS and rate of disease
progression with reduced final adult height. We have also
noted that disease severity is associated with nutritional
status, as determined by BMI, in patients with the
m.3243A.G mutation, although the overall BMI SD of
this patient group is well within normal limits.
It was interesting to note that patients with short
stature were more likely to have diabetes and cardio-
vascular involvement, whereas patients with a low BMI
had more severe symptoms such as seizures, encepha-
lopathy, and strokelike episodes, as noted previously
(16). Both short stature and low BMIwere associated with
hearing impairment and gastrointestinal disturbances.
Because adults often attain their final height before the
onset of overt disease, our findings suggest that otherwise
subclinical impairments inmitochondrial function can affect
growth and specifically the behavior of the chondrocyte.
There are a number of possible explanations for the
association between phenotype and stature. Muscle
function is known to affect skeletal integrity and bone
mass, but our data may reflect an impact of mitochon-
drial and associated muscle dysfunction on bone growth.
With this in mind, it is of interest that patients with the
milder Becker muscular dystrophy phenotype are taller
than those with Duchenne muscular dystrophy, and in
children with cerebral palsy, more profound motor
dysfunction is associated with slower growth (17, 18).
Increasing evidence in animal models shows the im-
portance of muscle contractions in longitudinal bone
growth; in one study mice with one limb paralyzed had a
significantly shorter limb length in the affected limb,
demonstrating that muscle loading has a role in stimu-
lating chondrocytes in the growth plate (19).
Although it is possible that reduced muscle mass
and exercise intolerance during childhood in patients
with early onset mitochondrial disease could affect the
growth plate, a more direct effect of abnormal mito-
chondrial function on chondrocyte function can also be
postulated. Hence, dysfunctional ATP synthesis within
the chondrocyte itself could be a mechanism leading to
poor growth and short stature. In the growth plate,
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hypertrophy and proliferation of chondrocytes are
closely regulated, and it is well recognized that in these
cells decreased ATP results in apoptosis (19). In patients
with mitochondrial disease this effect may result in in-
creased apoptosis and cell death in the growth plate, with
associated suboptimal growth. An increase in apoptosis
has been observed in the muscle samples of patients with
primary mitochondrial disorders, and a similar process
may affect the chondrocyte as a potential mechanism (20).
Another potential explanation for poor growth in
these patients is that abnormal mitochondrial function
affects GH production and secretion. There have been
numerous case reports of GH deficiency in patients with
mitochondrial disease in the nuclear, m.3243A.G, and
single large-scale mtDNA deletions (21–24). Postulated
mechanisms include the presence of mutated mtDNA in
the hypophysis, leading to pituitary dysfunction (21, 25).
Primary lesions affecting the hypothalamic GH releasing
factor cells have been reported in two patients with mito-
chondrial encephalomyopathy lactic acidosis and strokelike
episode, with increased GH production noted after the ad-
ministration of GH releasing factor (23). Treatment with
recombinant GH improved stature in a small number of
patients with mitochondrial disease, but there are no
larger-scale studies (23, 26, 27). Concerns have been
raised about possible long-term detrimental effects of
increased GH concentrations in mitochondrial disease,
with acute deteriorations reported in patients with KSS and
other mitochondrial rearrangements due to increased tissue
energy demands after administration (22, 26, 27).
Suboptimal nutrition and an inability to meet meta-
bolic energy demands could also influence stature and
body habitus, although overall BMI SD was above av-
erage. Gastrointestinal symptoms commonly reported by
patients with mitochondrial disease include reduced oral
intake due to poor appetite and early satiety. Dysphagia
of varying severity is also well recognized, affecting 48%
of patients and is very common in the m.3243A.G
subgroup (9, 28). The mechanism is believed to be
dysfunctional involvement of smooth muscle, peripheral
nerves, and central nervous system in swallowing. Gas-
troparesis, delayed gastric emptying, bacterial over-
growth, and intestinal pseudo-obstruction have also been
noted in this population (16). Malabsorption is com-
monly experienced by patients, and mtDNA defects have
been shown to impair human colonic epithelial function
(29). Together, thesemechanisms result in malabsorption
and reduced body mass. Our data also demonstrate that
there is an association between disease severity and BMI.
In the m.3243A.G subgroup, disease severity as mea-
sured by NMDAS is associated with a fall in BMI. We
also noted that patients with KSS, known for their
early onset of disease manifestations, are shorter, with a
lower BMI than those with CPEO, whose onset is often
Table 2. Correlation of Height and BMI SDs With Disease Manifestations
NMDAS Question
Height SD BMI SD
r 95% CI P n r 95% CI P n
Psychiatric involvement 20.10 20.19 to 20.02 0.016 545 20.06 20.15 to 0.03 0.193 447
Cerebellar ataxia 20.20 20.28 to 20.11 ,0.001a 536 20.06 20.15 to 0.04 0.238 442
Migraine 20.10 20.18 to 20.01 0.026 545 20.10 20.19 to 0.00 0.039 447
Cognition 20.28 20.36 to 20.20 ,0.001a 515 20.13 20.22 to 20.04 0.007 426
Neuropathy 20.01 20.10 to 0.07 0.785 538 0.07 20.02 to 0.16 0.128 443
Dysphonia or dysarthria 20.13 20.22 to 20.05 0.002 539 20.16 20.25 to 20.07 0.001a 442
Seizures 20.08 20.16 to 0.00 0.065 545 20.21 20.30 to 20.12 ,0.001a 447
Encephalopathy 20.09 20.18 to 20.01 0.031 545 20.22 20.31 to 20.13 ,0.001a 447
Strokelike episodes 20.10 20.18 to 20.01 0.025 545 20.22 20.31 to 20.13 ,0.001a 447
Pyramidal 20.19 20.27 to 20.11 ,0.001a 537 20.11 20.20 to 20.02 0.017 443
Extrapyramidal 20.13 20.21 to 20.05 0.002 537 20.02 20.12 to 0.07 0.604 443
Visual acuity 20.12 20.21 to 20.04 0.005 529 0.09 0.00 to 0.19 0.049 435
Ptosis 20.01 20.10 to 0.07 0.747 539 0.08 20.01 to 0.18 0.075 443
CPEO 0.02 20.07 to 0.10 0.701 540 0.05 20.04 to 0.14 0.288 443
Hearing impairment 20.24 20.32 to 20.16 ,0.001a 545 20.17 20.26 to 20.08 ,0.001a 447
Gastrointestinal disturbance 20.17 20.25 to 20.08 ,0.001a 545 20.17 20.26 to 20.08 ,0.001a 447
Myopathy 20.07 20.15 to 0.02 0.119 540 20.10 20.19 to 20.01 0.031 443
Diabetes 20.19 20.27 to 20.10 ,0.001a 545 0.02 20.07 to 0.11 0.649 447
Cardiovascular involvement 20.21 20.29 to 20.12 ,0.001a 495 20.07 20.16 to 0.03 0.170 414
Pearson correlations of height SD and BMI SD with comorbidities as defined by individual NMDAS questions. Estimated Pearson correlation coefficients
and uncorrected P values are shown. The Bonferroni corrected threshold of significance for correlations is 0.001 because 38 independent tests were
performed. Diseasemanifestations represent answers to questions from sections II and III of the NMDAS assessment, because these are physician assessed
and therefore more likely to be objective. Hearing impairment from section I was included, because this is the only assessment of this common mi-
tochondrial disease manifestation within the NMDAS.
aSignificant results.
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later in life (30). Body mass and muscle strength affect
mechanical loading, which is essential for bone remod-
eling and maintaining mineral density. Those with a
higher BMI have a greater bone mineral density because
of mechanical loading (9, 31).
As well as gastrointestinal symptoms, patients with
mitochondrial disease may have other comorbidities that
could theoretically affect growth and bone health (9, 32,
33). These include endocrinopathies such as hypopara-
thyroidism, hypothyroidism, and diabetes. However,
these endocrine disorders are variably expressed within
patients who have the same genotype. Indeed, phenotypic
heterogeneity and tissue-specific vulnerability are often
observed across both mtDNA and nuclear gene defects.
In this study, our finding that patients with mitochon-
drial disease caused by the m.3243A.G mutation are
generally shorter than patients with other genetic mutations
is entirely consistent with this phenotypic heterogeneity,
but the exact mechanism of such tissue-specific changes
remains elusive.
There is a growing understanding that the systemic effects
of stress and inflammation in chronic disease statesmay affect
growth (34). In adults with mitochondrial disease, hypo-
thyroidism is uncommon, andmitochondrial diabetes usually
develops after the age of 35 years and hence beyond the phase
of childhood and adolescence when growth occurs (35, 36).
Hypoparathyroidism is seen in severe childhood-onset KSS
and mitochondrial encephalomyopathy lactic acidosis and
strokelike episode, but in these patients short stature is caused
by multisystem involvement. Patients with severe mito-
chondrial disease are more likely to be receiving multiple
medications,whichmayalso affect growth; however, because
the majority of our patients attained final height before overt
disease onset, this potential mechanism is unlikely. The
prevalence of one risk factor affecting bone health in mito-
chondrial disease was estimated at 73% in one cohort, with
30% having four risk factors (33). Patients with mitochon-
drial disease are at elevated risk of osteoporosis, with more
than half of the adult population known to have at least one
risk factor (31).
Multiple comorbidities and associated stress could result
in elevated circulating levels of growth differentiation factor
15 (37). growth differentiation factor 15 has been cited as a
possible biomarker of mitochondrial disease (38, 39). It
inhibits the production of IGF-1 in the liver, limiting body
size in response to decreased energy availability. This
pathophysiological process could affect growth during
childhood and adolescence in the context of patients sub-
sequently diagnosed with a mitochondrial disorder.
Limitations
Missing data in height, weight, and NMDAS scores in
some patients may result in selection bias. However, there
was no significant difference between the mean NMDAS
score of our cohort (n = 537) and those excluded for having
no documented height (n = 36) (27 vs 33, P = 0.096).
We wondered whether the negative association be-
tween NMDAS score and stature might reflect the impact
of the disease process on progress through puberty with a
recorded height that was not representative of final adult
height in younger patients. An analysis of the association
between NMDAS score and height in older patients was
similar to the data as a whole, confirming that the as-
sociation was not simply caused by delayed pubertal
development and growth. At present, limited information
is available about growth in patients with mitochondrial
disease during childhood and adolescence.
Stature is multifactorial, and in the pediatric population
midparental height is often used by clinicians to determine a
child’s potential final adult height and to look for a possible
growth disorder. In our cohort no parental final height data
were available; it would be useful to consider whether
stature in those with a mitochondrial defect differed from
that of unaffected parents.
Intrauterine growth is known to affect final height. In
our cohort birthweight and gestation data were not
available. Studies looking at birth weight in mitochon-
drial disease have focused on patients with pediatric
mitochondrial disease and have shown that they are
significantly lighter than their counterparts; in one
study#22%were below the third percentile for weight at
birth (40, 41). We know that infants who are small for
gestational age often attain a shorter final height than
their larger counterparts, particularly if no catch-up
growth is demonstrated within the first years of life.
Our pregnancy study has recently shown that lower birth
weight was evident in the m.3243A.G group compared
with other genotypes. It is therefore possible that short
stature in patients with more severe mitochondrial dis-
ease is linked to smaller size at birth, and this is an area
that requires further study.
Because our data are predominantly single-point data,
the impact of loss of vertebral height due to osteoporosis and
aging is important to consider. We addressed this limitation
by correlating age at height measurement and height SDs
and found no significant correlation (r = 20.01; 95%
CI, 20.10 to 0.07; P = 0.80; n = 537). Nevertheless, it is
possible that current height is less than the maximally
attained height in a small number of older patientswho have
osteoporotic fracture, causing loss of vertebral height, or
simply the normal age-related change in adult height.
Conclusions
This is a comprehensive description of stature in adults
with mitochondrial disease. Numerous mechanisms for
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short stature can be postulated, including the impact of
muscle function on the growth plate, abnormal chon-
drocyte activity and suboptimal nutrition. To date the
definitive mechanism or mechanisms remain unknown.
We suspect that along with the impact of chronic
disease, abnormalities of growth inmitochondrial disease
also reflect abnormal chondrocyte behavior within the
growth plate. More animal mechanistic studies are
needed to confirm this suspicion. The role of hetero-
plasmy levels in chondrocytes remains to be explored.
Our findings suggest that height is a simple measure that
may have a predictive value for the disease burden in adult
mitochondrial disease. Additional observational analysis of
serial measurements of NMDAS scores, height, and weight
would help explore these associations in greater detail. Ac-
curate growth data may help to guide clinicians and families
toward the more appropriate use of targeted physiotherapy
programs in the future. Short stature may be an early in-
dicator of mitochondrial disease and should be considered
within the differential diagnosis to optimize patient care.
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